Anne‐Marie Heckel

This study identifies modified crRNA variants for precise targeting of point mutations in human mitochondrial DNA using CRISPR-Cas12a, showing effective discrimination and base editing in vitro and in human cells.

This paper demonstrates the use of a Type V CRISPR-Cas12a system to induce targeted deletions in human mitochondrial DNA, offering a potential therapeutic approach for mitochondrial disorders.